Literature DB >> 28423298

Bezlotoxumab and Recurrent Clostridium difficile Infection.

Mark Wilcox1, Mary-Beth Dorr2, Alison Pedley2.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28423298     DOI： 10.1056/NEJMc1702531

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

1.  Risk of Clostridium difficile Infection with Systemic Antimicrobial Therapy Following Successful Fecal Microbiota Transplant: Should We Recommend Anti-Clostridium difficile Antibiotic Prophylaxis?

Authors:  Jessica R Allegretti; Dina Kao; Emmalee Phelps; Brandi Roach; Justin Smith; Vincent C Ganapini; Zain Kassam; Huiping Xu; Monika Fischer
Journal:  Dig Dis Sci       Date:  2019-01-10       Impact factor: 3.199

2.  Detection of Newly Secreted Antibodies Predicts Nonrecurrence in Primary Clostridioides difficile Infection.

Authors:  F Eun-Hyung Lee; John L Daiss; Natalie S Haddad; Sophia Nozick; Geena Kim; Shant Ohanian; Colleen S Kraft; Paulina A Rebolledo; Yun Wang; Hao Wu; Adam Bressler; Sang Nguyet Thi Le; Merin Kuruvilla; Martin C Runnstrom; Richard P Ramonell; L Edward Cannon
Journal:  J Clin Microbiol       Date:  2022-03-16       Impact factor: 11.677

3.  Recommendations for the diagnosis and treatment of Clostridioides difficile infection: An official clinical practice guideline of the Spanish Society of Chemotherapy (SEQ), Spanish Society of Internal Medicine (SEMI) and the working group of Postoperative Infection of the Spanish Society of Anesthesia and Reanimation (SEDAR).

Authors:  E Bouza; J M Aguado; L Alcalá; B Almirante; P Alonso-Fernández; M Borges; J Cobo; J Guardiola; J P Horcajada; E Maseda; J Mensa; N Merchante; P Muñoz; J L Pérez Sáenz; M Pujol; E Reigadas; M Salavert; J Barberán
Journal:  Rev Esp Quimioter       Date:  2020-02-20       Impact factor: 1.553
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.